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Pounds (GBP). Cost of improved preservation technique was not
included in the model. RESULTS: IPTx may generate 4.18 and
1.19 QALY gain vs MM and CPTx respectively by increasing
heart transplantation rates and reducing the impact of CIT.
Treatment costs are reduced by 4476 GBP vs MM and increased
by 5768 GBP vs CPTx. CONCLUSION: Many patients die
on the waiting list due to the lack of transportability of hearts
from eligible donors. Improved preservation of explanted hearts
may generate 58′496 GBP of economic value per each heart
transplantation.
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OBJECTIVES: To assess the effects of various lipid-modifying
strategies on direct medical costs of coronary heart disease
(CHD) events among a representative patient cohort with estab-
lished CHD. METHODS: Model-based analysis, using data from
clinical trials, published literature, and national databases to
project CHD medical costs (emergency, inpatient, and outpa-
tient) over 5 years. The analysis focused on hypothetical cohorts
of 10,000 CHD patients (50 years of age or older) with any
abnormal lipid parameter (LDL-C, HDL-C, Non-HDL-C, and/or
TG). The expected number of CHD events was calculated using
the Framingham Heart Study equation for secondary prevention.
Age, sex, and coronary risk-factor data for patients with CHD
were obtained from a nationally-representative US health survey.
Direct medical costs were expressed in $US 2006, discounted
annually at 3%. The drugs of interest included simvastatin (S)
alone and ﬁxed-dose extended release niacin/simvastatin (ERN/
S), allowing an evaluation of increasing doses of S or adding a
second agent to S. RESULTS: Direct medical costs of CHD events
over 5 years are estimated to be approximately $3436 per patient
for patients treated with 20 mg of S. These costs would decrease
by 8.8% with 1000/20 mg of ERN/S. Compared to more aggres-
sive lipid therapy with 40 mg of S, 1000/40 mg of ERN/S would
decrease CHD costs by 9.1%. Relative to a maximum dose of
80 mg of S, the maximum dose of ERN/S (2000/40 mg) would
reduce CHD event costs by 11.2%. CONCLUSION: Intensifying
lipid-modifying therapy with ﬁxed-dose ERN/S combinations
would further reduce direct medical costs of CHD events more
effectively than S monotherapy in a secondary prevention popu-
lation. Further research on the cost-effectiveness of intensifying
dyslipidemia treatment is warranted.
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OBJECTIVES: Examine gender differences in resource use,
expenditures and mortality among U.S. Medicare patients fol-
lowing discharge from a hospital admission for congestive heart
failure (CHF). METHODS: Analyses were conducted on
national 5% sample of Medicare claims from January 1999 to
December 2001. A cohort that had an initial hospitalization with
a primary diagnosis of CHF was identiﬁed. Resource use at one
year preceding and following the initial CHF admission was
compared among males and females. Separate multivariate
regression models were developed by gender to assess the factors
associated with outcomes. Models included variables for patient
characteristics, comorbidity, compliance with routine care and
resource use in the year prior to CHF admission. RESULTS: A
majority of the 34,540 CHF patients were white (86%), one-half
were 80 years or older and approximately 58% were female.
Male CHF patients had a higher Charlson comorbidity score
compared to females (4.27 vs. 3.99; p < 0.0001). Females were
more likely than males to have an inpatient readmission within
365 days (58.6% vs. 41.2%; p = 0.016), an emergency depart-
ment visit within 180 days preceding (58.3% vs. 41.7%;
p = 0.0019) and following CHF admission (57.7% vs. 42.3%;
p = 0.035), physician ofﬁce visits within 365 days preceding
(58.5% vs. 41.5%; p = 0.0001) and following CHF admission
(57.7% vs. 42.3%; p = 0.0001). Females were also more likely
than males to die within 60 days (56.3% vs. 43.7%; p = 0.009),
90 days (56.5% vs. 43.5%; p = 0.006), 180 days (56.2%
vs. 43.8%; p = 0.0001) and 365 days (56.1% vs. 43.9%;
p < 0.0001) of the initial CHF admission. In multivariate models,
factors associated with health care resource use, expenditures
and mortality had similar trends in both gender models. CON-
CLUSION: There appears to be gender differences in resource
use and outcomes among CHF patients. Effort to better target
interventions, diagnostic and therapeutic, among patients
at higher risk of adverse outcomes carries potential for cost-
effective management of CHF patients.
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OBJECTIVES: Determine hypertension-related costs and cost-
effectiveness ratios of pharmaceutical treatment for patients with
hypertension in Greece METHODS: Data was derived from the
PharmacoECOnomic Assessment of Prognostic Risk Occupa-
tional Survey (ECON-APROS), a cross-country prospective
study. The sample included individuals 30–75 yrs old, diagnosed
with hypertension (Systolic Blood Pressure >140 mmHg and/or
Diastolic Blood Pressure >90 mmHg), who were treated and
monitored for a period of 1 year after the diagnosis. Patients
were separated in two subgroups: a) those with uncomplicated
hypertension (N = 1243) and b) those with complications e.g.
CVD, CHD, MI etc. (N = 122). Demographic, clinical and socio-
economic information was collected. Cost analysis was based on
the direct cost estimations and the measurement of the effective-
ness was based on the absolute reductions in the mean SBP for
each subgroup after 1 year of treatment. The perspective of the
Greek NHS was taken. Tariffs are referred to 2006 prices and
costs are expressed in Euros. RESULTS: Mean direct cost per
patient suffering from uncomplicated hypertension was esti-
mated at 687€ per year while for the second subgroup was
signiﬁcantly higher at 1771€ per year. Mean reduction in the
patients’ Systolic Blood Pressure was 32.58 mmHg for the ﬁrst
subgroup and 34.38 mmHg for the second. Cost-effectiveness
ratios for each subgroup were estimated at 21.1€/mmHg and
51.7€/mmHg, respectively, for every 1 mmHg lowering of the
Systolic Blood Pressure. CONCLUSION: The long term conse-
quences of untreated hypertension are both life-threatening, for
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